Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12731996 | 0.91 | MEN1 (0.38) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1660988 | 0.91 | NPC1 (0.44) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12732002 | 0.87 | MEN1 (0.35) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14351835 | 0.85 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL19367696 | 0.85 | CNR2 (0.41) | CNR2 | |
| SCHEMBL22444705 | 0.85 | CNR2 (0.41) | CNR2 | |
| SCHEMBL8790823 | 0.79 | CNR2 (0.44) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9396559 | 0.79 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14821169 | 0.78 | CNR2 (0.42) | NPC1RAB9ASMN1; SMN2MAPTCNR2 | |
| SCHEMBL14498459 | 0.78 | MAPT (0.38) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1958940-B1 | CONDENSATION REACTION BY METAL CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-7888513-B2 | Condensation reaction by metal catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20090198070-A1 | Condensation Reaction by Metal Catalyst | OSAKA UNIVERSITY (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1958940-A1 | CONDENSATION REACTION BY METAL CATALYST | Takasago International Corporation (JP) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198070-A1 | Condensation Reaction by Metal Catalyst | C9, CBR3, C1R | MEN1 120/4885KMT2A 1055/4885NPC1 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.